2025-07-29 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided, presented in English with a focus on key figures and concise insights.

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

### 1. Performance Relative to S&P 500 (VOO)

*   **JNJ Cumulative Return:** 22.45%
*   **VOO Cumulative Return:** 99.63%
*   **Absolute Performance Difference:** -75.7%
*   **Relative Performance Deviation:** 7.1

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. A relative deviation of 7.1 indicates JNJ's underperformance is near the low end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap (B) |
| :--------- | :------ | :---- | :------ | :---- | :------ |
| 2015-2017  | 28.0%   | 56.1% | -1.0%   | -0.0  | 336.5   |
| 2016-2018  | 8.0%    | 56.6% | -10.0%  | 0.0   | 310.8   |
| 2017-2019  | 18.0%   | 56.6% | -12.0%  | 0.7   | 351.3   |
| 2018-2020  | 12.0%   | 59.2% | -8.0%   | 0.3   | 379.0   |
| 2019-2021  | 32.0%   | 59.6% | -16.0%  | 0.2   | 412.0   |
| 2020-2022  | 7.0%    | 61.4% | 5.0%    | 0.2   | 425.4   |
| 2021-2023  | -15.0%  | 61.4% | -33.0%  | 0.4   | 377.5   |
| 2022-2024  | -35.0%  | 61.4% | -61.0%  | 0.3   | 348.3   |
| 2023-2025  | -5.0%   | 70.1% | -56.0%  | 0.2   | 400.3   |

**Analysis:**

*   **CAGR:** Shows varied annual growth rates, with recent periods showing negative returns.
*   **MDD:** Consistently high Maximum Drawdown values indicate significant potential losses.
*   **Alpha:** Predominantly negative alpha values suggest underperformance relative to a risk-adjusted benchmark.
*   **Beta:** Low beta values close to zero imply JNJ's price is not strongly correlated with the overall market.
*   **Cap:** Market capitalization fluctuates over time.

### 2. Recent Stock Price Movement

*   **Current Price:** 166.22
*   **Previous Close:** 168.3
*   **Change:** -1.24
*   **5-Day Moving Average:** 168.22
*   **20-Day Moving Average:** 160.56
*   **60-Day Moving Average:** 155.81

**Analysis:** The stock price has decreased slightly compared to the previous close. The 5-day moving average is above the current price, while the 20-day and 60-day moving averages are below, indicating a potential short-term downward trend but overall longer-term upward trend.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3286 (Low Risk)
*   **RSI:** 70.25 (Approaching overbought territory)
*   **PPO:** 0.5055
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence (20-day):** 0.4 (+) â€“ Short-term increase
*   **Expected Return:** -398.1% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a low-risk environment. The RSI is approaching overbought levels, which could indicate a potential pullback. The hybrid signal suggests a cautious buying strategy. The short-term relative divergence indicates some recent positive price movement. The extremely negative expected return is a major concern, suggesting a significant underperformance relative to the S&P 500 over the long term. The price drop reflects recent market volatility.

### 4. Recent News & Significant Events

*   **2025-07-27:** Major business developments, regulatory changes, or market events.
*   **2025-07-29:** Analyst discussions on recent performance and outlook.
*   **2025-07-26:** Notable stock volatility.
*   **2025-07-25:** Experts highlighting risks and opportunities, advising monitoring.

**Analysis:** Recent news indicates volatility and significant events impacting JNJ. Monitoring these developments is crucial.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue    |
| :--------- | :--- | :--------- |
| 2025-07-24 | 2.3  | $23.74B    |
| 2025-04-23 | 4.57 | $21.89B    |
| 2024-10-23 | 1.12 | $22.47B    |
| 2024-07-25 | 1.95 | $22.45B    |
| 2025-07-24 | 1.95 | $22.45B    |

**Analysis:** Earnings per share (EPS) and revenue figures have fluctuated. The most recent EPS figure is in line with the previous year.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :------------ |
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
| :----------- | :---------- | :------- |
| 2025-06-30   | $78.47B    | 7.06%    |
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |
| 2024-06-30   | $71.54B    | 6.55%    |

**Analysis:**  Revenue and profit margins have been relatively stable. Return on equity (ROE) has fluctuated, indicating changes in profitability relative to shareholder equity.

### 7. Overall Summary

Based on the provided data, JNJ has underperformed the S&P 500 significantly. Recent news suggests volatility and potential impactful events. While the MRI indicates low market risk, the RSI is approaching overbought conditions. The extremely negative expected return is a significant concern. Recent revenue and profitability metrics are stable, but ROE has fluctuated. JNJ's Beta indicates that the price is not strongly correlated with the overall market.

**Recommendation:** A cautious approach is warranted. Investors should closely monitor news, earnings reports, and industry trends related to JNJ before making investment decisions. Further investigation is needed to understand the drivers behind the negative expected return.
